Journal Article DKFZ-2025-01430

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Do We Need Early Detection of Grade Group 2 Prostate Cancer in a Screening Program for Young Men? Results from the PROBASE Screening Trial.

 ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;

2025
Elsevier Amsterdam

European urology oncology nn, nn () [10.1016/j.euo.2025.06.007]
 GO

This record in other databases:

Please use a persistent id in citations: doi:

Abstract: In general, low-risk and favorable intermediate-risk prostate cancers (PCs; International Society of Urological Pathology grade group [GG] 1 and GG 2) are slow-growing cancers with low metastatic potential. Active surveillance is recommended for GG 1 PC and can be recommended for GG 2 PC in the absence of adverse pathological parameters. Therefore, the question arises as to when low-grade PC should be detected in a screening setting. We conducted an analysis of the group with intermediate prostate-specific antigen (PSA) risk (1.5-2.99 ng/ml) from the PROBASE screening trial for young men (starting age 45 yr) and evaluated 159 biopsies performed for confirmed PSA ≥3 ng/ml in the first two biennial screening rounds. Of these biopsies, 37% were positive, with 78% (46/59) showing GG 1 or GG 2 disease. Only 0.8% of men with intermediate risk (13 of 1661 men screened) had GG 3-5 PC and would have experienced a delay in diagnosis of between 1 and 3 yr if screening were performed at 5-yr intervals. These results suggest that the screening interval could be extended from 2 yr to 5 yr for men aged 45 yr at intermediate risk, similar to the interval for men at low risk (PSA <1.5 ng/ml). This would reduce unnecessary testing and overdiagnosis in nearly 10% of the screening population aged 45 yr.

Keyword(s): Grade group ; Intermediate risk ; International Society of Urological Pathology ; Prostate cancer ; Screening

Classification:

Note: #EA:C130#LA:C130# / epub

Contributing Institute(s):
  1. Personalisierte Früherkennung des Prostatakarzinoms (C130)
  2. C060 Biostatistik (C060)
  3. E010 Radiologie (E010)
  4. Epidemiologie von Krebs (C020)
Research Program(s):
  1. 313 - Krebsrisikofaktoren und Prävention (POF4-313) (POF4-313)

Appears in the scientific report 2025
Database coverage:
Medline ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Essential Science Indicators ; IF >= 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Institute Collections > E010
Institute Collections > C020
Public records
Publications database

 Record created 2025-07-17, last modified 2025-07-18



Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)